Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PER2 | O15055 | 1/20 | 0.35 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29760366 | 0.89 | TSHR (0.55) | TSHRKDM4EAPEX1BLMPIK3CD | |
| SCHEMBL908640 | 0.82 | HSD17B10 (0.41) | KDM4EPIK3CDNAAAMAPK1 | |
| SCHEMBL22607649 | 0.81 | KDM4E (0.44) | TSHRKDM4EPIK3CDNAAAMAPK1 | |
| SCHEMBL15125171 | 0.80 | PIK3CD (0.42) | KDM4EPIK3CDNAAANPC1RAB9A | |
| SCHEMBL11983582 | 0.80 | PIK3CD (0.42) | KDM4EPIK3CDNAAANPC1RAB9A | |
| SCHEMBL7769442 | 0.80 | KDM4E (0.39) | KDM4EPIK3CDNAAANPC1RAB9A | |
| SCHEMBL2825590 | 0.79 | ALDH1A1 (0.41) | TSHRKDM4EPIK3CDNAAANPC1 | |
| SCHEMBL13096630 | 0.77 | NAAA (0.42) | KDM4EPIK3CDNAAANPC1RAB9A | |
| SCHEMBL15113635 | 0.76 | PIK3CD (0.46) | KDM4EPIK3CDNAAANPC1RAB9A | |
| SCHEMBL13086572 | 0.76 | PIK3CD (0.40) | KDM4EPIK3CDNAAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008099165-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | WO | claimed |
| US-11365199-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | MERCK PATENT GMBH (DE) | 2022-06-21 | — | — | US | disclosed |
| WO-2021097117-A2 | NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-05-20 | — | — | WO | disclosed |
| EP-3013832-B1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-11-04 | — | — | EP | disclosed |
| US-20180354965-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-12-13 | — | — | US | disclosed |
| US-10081637-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | MERCK PATENT GMBH (DE) | 2018-09-25 | — | — | US | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20160152626-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| EP-3013832-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | Merck Patent GmbH (DE) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014209980-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2014-12-31 | — | — | WO | disclosed |
| EP-0765879-B1 | 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests | SANKYO CO (JP) | 2001-02-14 | — | — | EP | disclosed |
| US-5861429-A | MITICIDES AND ANTHELMINTICS | SANKYO COMPANY, LIMITED (JP) | 1999-01-19 | — | — | US | disclosed |
| EP-0765879-A1 | 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests | SANKYO COMPANY LIMITED (JP) | 1997-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365199-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | FSHR, GNRHR, LHCGR | TSHR 10/4885KDM4E 2303/4885APEX1 3696/4885 |
| US-10081637-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | FSHR, GNRHR, LHCGR | TSHR 10/4885KDM4E 2303/4885APEX1 3696/4885 |
| US-20160152626-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | TSHR 10/4885KDM4E 2303/4885APEX1 3696/4885 |
| US-20180354965-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | TSHR 10/4885KDM4E 2303/4885APEX1 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.